



EJW

ATTORNEY'S DOCKET NUMBER: 2003080-0071 (SK-744-CON4)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Danishefsky *et al.* Examiner: Solola, T. A.
Serial No.: 10/004,571 Art Unit: 1626
Filed: December 4, 2001
For: Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449 (21 page);
2. Supplemental Information Disclosure Statement (5 pages);
3. Transmittal Letter (1 page);
4. Cited Art (434); and
5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,


C. Hunter Baker, M.D., Ph.D.
Registration Number 46,533

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
(617) 248-4000

Dated: *2/9/2005*
3814598

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2-9-05 Sandra Saccoccia

Date Signature

Sandra Saccoccia

Typed or Printed Name of person signing certificate



ATTORNEY'S DOCKET NUMBER: 2003080-0071 (SK-744-CON4)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Danishefsky *et al.* Examiner: Solola, T. A.
Serial No.: 10/004,571 Art Unit: 1626
Filed: December 4, 2001
For: Synthesis of Epothilones, Intermediates Thereto, Analogues and Uses Thereof

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- An *original* Information Disclosure Statement; or
 A *supplemental* Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2-9-05
Date

Sandra Saccoccia
Signature

Sandra Saccoccia

Name of Person Signing

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- [X] Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- [] Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
- [] Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
- [X] Before the mailing of a first Office action on the merits; or
- [] Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- [] Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- [] Certifies that *either*:
- [] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual

designated in § 1.56(c) more than three months prior to the filing of
the information disclosure statement; or

[] Includes herewith the fee set forth in § 1.17(p),

[] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under
§ 1.113, a notice of allowance under § 1.311, or an action that otherwise closes
prosecution in the application; Applicant hereby *both*:

[] Certifies that *either*:

[] each item of information contained in the information disclosure
statement was first cited in any communication from a foreign
patent office in a counterpart foreign application not more than
three months prior to the filing of the information disclosure
statement; or

[] That no item of information contained in the information
disclosure statement was cited in a communication from a foreign
patent office in a counterpart foreign application, and, to the
knowledge of the person signing the certification after making
reasonable inquiry, no item of information contained in the
information disclosure statement was known to any individual
designated in § 1.56(c) more than three months prior to the filing of
the information disclosure statement; and

[] Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [X] A copy of each cited reference not indicated with an asterisk is included;
[] Copies of references indicated with an asterisk on the attached form PTO-1449
are not included pursuant to 37 CFR § 1.98(d) because they were previously
provided to the United States Patent Office in an Information Disclosure
Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the
following patent application that is relied upon in the present case for an earlier
effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- [] Copies of English translations of one or more non-English references are
included.

Applicant hereby makes the following additional information of record in the above-identified
application:

Applicant certifies that the Information Disclosure Statement *either*:

- [] Does not contain non-English language citations;
[] Includes one or more translations of a non-English citation; or
[X] Does contain non-English language citations, of which the following is a concise
explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: 2/9/2005



C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
(617) 248-5000
(617) 248-4000

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571	
			APPLICANT: Danishefsky <i>et al.</i>		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			FILING DATE: December 4, 2001	GROUP: 1626	
U.S. PATENT DOCUMENTS					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	6,090,601	Gustafsson	July 18, 2000	435	183
	6,096,757	Bishop	August 1, 2000	514	290
	6,117,659	Ashley	September 12, 2000	435	155
	6,121,029	Schupp	September 19, 2000	435	183
	6,211,412	Georg	April 3, 2001	568	309
	6,221,641	Khosla	April 24, 2001	435	193
	6,251,636	Betlach	June 26, 2001	435	76
	6,262,107	Li	July 17, 2001	514	449
	6,280,999	Gustafsson	August 28, 2001	435	252.3
	6,407,103	Nugiel <i>et al.</i>	June 18, 2002	514	232.8
	6,419,692	Yang <i>et al.</i>	July 16, 2002	623	115
	6,441,186	Nicolaou <i>et al.</i>	August 27, 2002	548	204
	6,457,303	Georg <i>et al.</i>	October 1, 2002	56	465
	6,489,314	Ashley <i>et al.</i>	December 3, 2002	514	183
	6,498,257	Vite <i>et al.</i>	December 24, 2002	548	205
	6,576,651	Bandyopadhyay <i>et al.</i>	June 10, 2003	514	365
	6,596,875	White <i>et al.</i>	July 22, 2003	548	204
	6,670,384	Bandyopadhyay <i>et al.</i>	December 30, 2003	514	365
	6,683,100	Van Hoogeveest	January 27, 2004	514	365
	6,686,380	Lee	February 3, 2004	514	365
	6,689,802	DiMarco <i>et al.</i>	February 10, 2004	514	365
	6,719,540	Regueiro-Ren <i>et al.</i>	April 13, 2004	417	365
	6,723,854	Danishefsky <i>et al.</i>	April 20, 2004	548	203
	6,727,276	Lee	April 27, 2004	514	540
	6,730,699	Li <i>et al.</i>	May 4, 2004	514	449
	6,730,803	Iwasaki <i>et al.</i>	May 4, 2004	558	442
	6,780,620	Li <i>et al.</i>	August 24, 2004	435	117

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>			
		FILING DATE: December 4, 2001	GROUP: 1626		
U.S. PATENT APPLICATIONS					
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
	2002/0086812	Schweinfest et al.	July 4, 2002		
	2002/0115686	Hoogevest	August 22, 2002		
	2002/0119202	Hunter et al.	August 29, 2002		
	2002/0137152	Santi et al.	September 26, 2002		
	2002/0143038	Bandyopadhyay <i>et al.</i>	October 3, 2002		
	2002/0147197	Newman et al.	October 10, 2002		
	2002/0156110	Arslanian et al.	October 24, 2002		
	2002/0156289	Georg et al.	October 24, 2002		
	2002/0164377	Hunter et al.	November 7, 2002		
	2002/0165258	Lee	November 7, 2002		
	2002/0165257	Lee	November 7, 2002		
	2002/0165265	Hunter et al.	November 7, 2002		
	2002/0165415	Georg et al.	November 7, 2002		
	2002/0169125	Leung et al.	November 14, 2002		
	2002/0169135	Pardee et al.	November 14, 2002		
	2002/0169190	Bandyopadhyay et al.	November 14, 2002		
	2002/0177615	Bandyopadhyay et al.	November 28. 2002		
	2002/0192778	Schupp <i>et al.</i>	December 19, 2002		
	2002/0193361	Ashley <i>et al.</i>	December 19, 2002		
	2002/0197261	Li <i>et al.</i>	December 26, 2002		
	2002/0198141	McChesney <i>et al.</i>	December 26, 2002		
	2003/0191089	Regueiro-Ren <i>et al.</i>	October 9, 2003		
	2003/0187273	White <i>et al.</i>	October 2, 2003		
	2003/0139460	Schwede <i>et al.</i>	July 24, 2003		
	2003/0134883	Myles <i>et al.</i>	July 17, 2003		
	2003/0130178	Li <i>et al.</i>	July 10, 2003		
	2003/0130170	Li <i>et al.</i>	July 10, 2003		

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	2003/0124055	Li <i>et al.</i>	July 3, 2003	
	2003/0125362	Danishefsky <i>et al.</i>	July 3, 2003	
	2003/0113335	Li <i>et al.</i>	June 19, 2003	
	2003/0114363	Li <i>et al.</i>	July 3, 2003	
	2003/0114450	Santi <i>et al.</i>	June 19, 2003	
	2003/0114504	Webster <i>et al.</i>	June 19, 2003	
	2003/0114518	Li <i>et al.</i>	June 19, 2003	
	2003/0105330	Danishefsky <i>et al.</i>	June 5, 2003	
	2003/0109500	Pero <i>et al.</i>	June 12, 2003	
	2003/0096381	Julien <i>et al.</i>	May 22, 2003	
	2003/0073677	Lee	April 17, 2003	
	2003/0073617	Li <i>et al.</i>	April 17, 2003	
	2003/0073615	Li <i>et al.</i>	April 17, 2003	
	2003/0073205	Arslanian <i>et al.</i>	April 17, 2003	
	2003/0060623	Vite <i>et al.</i>	March 27, 2003	
	2003/0054977	Kumar <i>et al.</i>	March 20, 2003	
	2003/0049841	Short <i>et al.</i>	March 13, 2003	
	2003/0045711	Ashley <i>et al.</i>	March 6, 2003	
	2003/0036515	Pardee <i>et al.</i>	February 20, 2003	
	2003/0036177	Strohhacker	February 20, 2003	
	2003/0004338	Li <i>et al.</i>	January 2, 2003	
	2003/0004209	Hunter <i>et al.</i>	January 2, 2003	
	2003/0003094	Hunter <i>et al.</i>	January 2, 2003	
	2004/0023345	Vite <i>et al.</i>	February 5, 2004	
	2004/0024032	Voi <i>et al.</i>	February 5, 2004	
	2004/0024033	O'Reilly <i>et al.</i>	February 5, 2004	
	2004/0030147	White <i>et al.</i>	February 12, 2004	
	2004/0038324	Atadja <i>et al.</i>	February 26, 2004	
	2004/0039026	Nicolaou <i>et al.</i>	February 26, 2004	
	2004/0044203	Wittman <i>et al.</i>	March 4, 2004	

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>			
		FILING DATE: December 4, 2001		GROUP: 1626	
	2004/0044221	Danishefsky <i>et al.</i>	March 4, 2004		
	2004/0049051	Hoefle <i>et al.</i>	March 11, 2004		
	2004/0053910	Danishefsky <i>et al.</i>	March 18, 2004		
	2004/0053978	Lee <i>et al.</i>	March 18, 2004		
	2004/0053995	Danishefsky <i>et al.</i>	March 18, 2004		
	2004/0054186	Das <i>et al.</i>	March 18, 2004		
	2004/0087610	Pardee <i>et al.</i>	May 6, 2004		
	2004/0087634	Hoefle <i>et al.</i>	May 6, 2004		
	2004/0092478	Rothermel <i>et al.</i>	May 13, 2004		
	2004/0092514	Velaparthi <i>et al.</i>	May 13, 2004		
	2004/0092560	Hoefle <i>et al.</i>	May 13, 2004		
	2004/0097517	Dwyer <i>et al.</i>	May 20, 2004		
	2004/0102451	Guzi <i>et al.</i>	May 27, 2004		
	2004/0102452	Guzi <i>et al.</i>	May 27, 2004		
	2004/0102495	Danishefsky <i>et al.</i>	May 27, 2004		
	2004/0106624	Guzi <i>et al.</i>	June 3, 2004		
	2004/0106985	Jang	June 3, 2004		
	2004/0116442	Guzi <i>et al.</i>	June 17, 2004		
	2004/0126379	Adolf <i>et al.</i>	July 1, 2004		
	2004/0127432	Nicolaou <i>et al.</i>	July 1, 2004		
	2004/0132146	Benigni <i>et al.</i>	July 8, 2004		
	2004/0133271	Jang	July 8, 2004		
	2004/0132692	Sherrill <i>et al.</i>	July 8, 2004		
	2004/0132736	Guzi <i>et al.</i>	July 8, 2004		
	2004/0132754	Brandt <i>et al.</i>	July 8, 2004		
	2004/0142931	Vite <i>et al.</i>	July 22, 2004		
	2004/0142990	Hofmann <i>et al.</i>	July 22, 2004		
	2004/0152708	Li <i>et al.</i>	August 5, 2004		
FOREIGN PATENT DOCUMENTS					
Examiner's	Document No.	Country	Date	Translation	

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001		GROUP: 1626
				Yes
	DE 41 38 042	Germany	19 November 1991	
	DE 196 07 702	Germany	29 February 1996	
	DE 196 38 870	Germany	23 September 1996	
	DE 197 01 758	Germany	20 January 1997	
	DE 197 13 970	Germany	04 April 1997	
	DE 197 20 312	Germany	15 May 1997	
	DE 197 26 627	Germany	17 June 1997	
	DE 197 35 574	Germany	09 August 1997	
	DE 197 35 575	Germany	09 August 1997	
	DE 197 35 578	Germany	09 August 1997	
	DE 197 44 135	Germany	29 September 1997	
	DE 197 49 717	Germany	31 October 1997	
	DE 197 51 200	Germany	13 November 1997	
	DE 198 13 821	Germany	20 March 1998	
	DE 198 21 954	Germany	15 May 1998	
	DE 198 33 750	Germany	16 July 1998	
	DE 198 46 493	Germany	09 October 1998	
	DE 198 30 060	Germany	30 June 1998	
	DE 198 49 464	Germany	21 October 1998	
	DE 199 08 763	Germany	18 February 1999	
	DE 199 08 765	Germany	18 February 1999	
	DE 199 08 767	Germany	19 October 2000	
	DE 199 23 001	Germany	13 May 1999	
	DE 199 30 111	Germany	01 July 1999	
	DE 199 54 228	Germany	04 November 1999	
	DE 199 54 230	Germany	04 November 1999	
	DE 100 51 136	Germany	16 October 2000	
	DE 100 15 836	Germany	27 March 2000	

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	DE 100 20 517	Germany	19 April 2000	
	DE 100 20 899	Germany	20 April 2000	
	EP 1 440 973	Europe	July 28, 2004	
	EP 1 428 826	Europe	June 16, 2004	
	EP 1 407 784	Europe	April 14, 2004	
	EP 1 386 922	Europe	February 4, 2004	
	EP 1 340 498	Europe	September 3, 2003	
	EP 1 275 648	Europe	15 January 2003	
	EP 1 201 666	Europe	02 May 2002	
	EP 1 186 606	Europe	17 March 2002	
	EP 1 121 364	Europe	13 March 2002	
	EP 1 001 951	Europe	25 September 2002	
	EP 0 975 638	Europe	07 August 2002	
	EP 0 975 622	Europe	09 October 2002	
	WO 04/080458	International	September 23, 2004	
	WO 04/063151	International	July 29, 2004	
	WO 04/061116	International	July 22, 2004	
	WO 04/056832	International	July 8, 2004	
	WO 04/054622	International	July 1, 2004	
	WO 04/054514	International	July 1, 2004	
	WO 04/052401	International	June 24, 2004	
	WO 04/030620	International	April 15, 2004	
	WO 04/028610	International	April 8, 2004	
	WO 04/028582	International	April 8, 2004	
	WO 04/025254	International	April 1, 2004	
	WO 04/026877	International	April 1, 2004	
	WO 04/026872	International	April 1, 2004	
	WO 04/026867	International	April 1, 2004	
	WO 04/026310	International	April 1, 2004	
	WO 04/026229	International	April 1, 2004	

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	WO 04/024735	International	March 25, 2004	
	WO 04/022560	International	March 18, 2004	
	WO 04/022080	International	March 18, 2004	
	WO 04/022062	International	March 18, 2004	
	WO 04/018635	International	March 4, 2004	
	WO 04/016269	International	February 26, 2004	
	WO 04/012735	International	February 12, 2004	
	WO 03/084536	International	October 16, 2003	
	WO 03/078411	International	September 25, 2003	
	WO 03/077903	International	September 25, 2003	
	WO 03/075899	International	September 18, 2003	
	WO 03/074521	International	September 12, 2003	
	WO 03/074053	International	September 12 2003	
	WO 03/070170	International	13 February 2002	
	WO 03/018002	International	06 March 2003	
	WO 03/014068	International	20 February 2003	
	WO 03/014063	International	20 February 2003	
	WO 03/007924	International	30 January 2003	
	WO 02/098868	International	14 May 2002	
	WO 02/096281	International	December 5, 2004	
	WO 02/072085	International	19 September 2002	
	WO 02/067941	International	06 September 2002	
	WO 02/046196	International	13 June 2002	
	WO 02/030356	International	April 18, 2002	
	WO 01/010412	International	02 August 2000	
	WO 01/007439	International	24 July 2000	
	WO 00/071521	International	15 May 2000	
	WO 00/066589	International	01 May 2000	
	WO 00/058254	International	23 March 2000	
	WO 00/057874	International	20 March 2000	

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	WO 00/049020	International	18 February 2000	
	WO 00/049019	International	18 February 2000	
	WO 00/047584	International	11 February 2000	
	WO 00/039276	International	21 December 1999	
	WO 00/037473	International	20 December 1999	
	WO 00/031247	International	19 November 1999	
	WO 00/000485	International	30 June 1999	
	WO 99/067253	International	21 June 1999	
	WO 99/066028	International	16 June 1999	
	WO 99/065913	International	18 June 1999	
	WO 99/059985	International	25 November 1999	
	WO 99/058534	International	07 May 1999	
	WO 99/054319	International	05 April 1999	
	WO 99/054318	International	05 April 1999	
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Ahmed <i>et al.</i> , "Total Synthesis of the Microtubule Stabilizing Antitumor Agent Laulimalide and Some Nonnatural Analogues: The Power of Sharpless' Asymmetric Epoxidation" <i>J. Org. Chem.</i> 68 :3026-3042, 2003.			
	Altmann <i>et al.</i> , "Epothilones and Their Analogs-Potential New Weapons in the Fight Against Cancer" <i>Chimia</i> , 54 :612-621, 2000.			
	Altmann <i>et al.</i> , "Synthesis and Biological Evaluation of Highly Potent Analogues of Epothilones B and D" <i>Bioorg. Med. Chem. Lett.</i> 10 (24):2765-2768, 2000.			
	Altmann <i>et al.</i> , "Epothilones and Related Structures-A New Class of Microtubule Inhibitors with Potent <i>in vivo</i> Antitumor Activity" <i>Biochim. Biophys. Acta</i> , 1470 (3):M79-M91, 2000.			
	Altmann <i>et al.</i> , "Synthetic and Semisynthetic Analogs of Epothilones: Chemistry and Biological Activity" <i>Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, ORGN-287</i> , 1999.			
	Altmann <i>et al.</i> , "Microtubule-Stabilizing Agents: A Growing Class of Important Anticancer Drugs" <i>Curr. Opin. Chem. Biol.</i> , 5 (4):424-431, August 2001.			
	Appendino <i>et al.</i> , "The Synthesis of Epothilones: Highlights from a Year's Race" <i>Chemtracts</i> 11 (9):678-696, 1998.			
	Arslanian <i>et al.</i> , "A New Cytotoxic Epothilone from Modified Polyketide Synthases			

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
<p>Heterologously Expresssed in <i>Myxococcus xanthus</i>" <i>J. Nat. Prod.</i> 65:1061-1064, 2002.</p> <p>Avila <i>et al.</i>, "The Use of Microtubule Poisons on Tumor Cells" <i>Cancer J.</i> 10(6):315-318, 1997.</p> <p>Awada <i>et al.</i>, "New Cytotoxic Agents and Molecular-Targeted Therapies in the Treatment of Metastatic" <i>Breast Cancer Review</i> 4-15, 2002.</p> <p>Baggiolini <i>et al.</i>, "Stereocontrolled Total Synthesis of 1α, 25-Dihydroxycholecalciferol and 1α, 25-Dihydroxyergocalciferol" <i>J. Org. Chem.</i> 51:3098-3108, 1986.</p> <p>Baik <i>et al.</i>, "Diastereoselective Cobalt-Catalyzed Aldol and Michael Cycloreductions" <i>J. Am. Chem. Soc.</i> 123:5112-5113, 2001.</p> <p>Balog <i>et al.</i>, "A Novel Aldol Condensation with 2-Methyl-4-Pentenal and Its Application to an Improved Total Synthesis of Epothilone B" <i>Angew. Chem. Int. Ed.</i> 37(19):2675-2678, 1998.</p> <p>Balog <i>et al.</i>, "Total Synthesis of Epothilone A" <i>Angew. Chem. Int. Ed.</i> 61:2801-2803, 1996.</p> <p>Bellemin-Laponnaz <i>et al.</i>, "The Kinetic Resolution of Allylic Alchols by a Non-Enzymatic Acylation Catalyst: Application to Natural Product Synthesis" <i>Chem. Commun.</i> 12:1009-1010, 2000.</p> <p>Bertinato <i>et al.</i>, "Studies Toward a Synthesis of Epothilone A: Stereocontrolled Assembly of the Acyl Region and Models for Macrocyclization" <i>J. Org. Chem.</i> 61:8000-8001, 1996.</p> <p>Beyer <i>et al.</i>, "Metabolic Diversity in Myxobacteria" <i>Biochim. Biophys. Acta</i> 1445(2):185-195, 1999.</p> <p>Biswas <i>et al.</i>, "Highly Concise Routes to Epothilones: The Total Synthesis and Evaluation of Epothilone 490" <i>J. Am. Chem. Soc.</i> 124:9825-9832, 2002.</p> <p>Blum <i>et al.</i>, "In vivo Metabolism of Epothilone B in Tumor-Bearing Nude Mice: Identification of Three New Epothilone B Metabolites by Capillary High-Pressure Liquid Chromatography/Mass Spectrometry/Tandem Mass Spectrometry" <i>Rapid Commun. Mass Spectrom.</i> 15(1):41-49, 2001.</p> <p>Bocci <i>et al.</i>, "Protracted Low-Dose Effects on Human Endothelial Cell Proliferation and Survival in Vitro Reveal a Selective Antiangiogenic Window for Various Chemotherapeutic Drugs" <i>Cancer Research</i> 62:6938-6943, 2002.</p> <p>Boddy <i>et al.</i>, "Epothilone C. Macrolactonization and Hydrolysis Are Catalyzed by the Isolated Thioesterase Domain of Epothilone Polyketide Synthase" <i>J. Am. Chem. Soc.</i> 125:3428-3429, 2002.</p> <p>Bode <i>et al.</i>, "Stereoselective Syntheses of Epothilones A and B via Directed Nitrile Oxide Cycloaddition" <i>J. Am. Chem. Soc.</i> 123(15):3611-3612, 2001.</p> <p>Bode <i>et al.</i>, "Stereoselective Syntheses of Epothilones A and B via Nitrile Oxide Cycloadditions and Related Studies" <i>J. Org. Chem.</i>, 66(19):6410-6424, 2001.</p> <p>Bornscheuer <i>et al.</i>, "Directed Evolution of an Esterase for the Stereoselective Resolution of a Key Intermediate in the Synthesis of Epothilones" <i>Biotechnol. Bioeng.</i> 58(5):554-559, 1998.</p> <p>Borzilleri <i>et al.</i>, "A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio and Stereoselective Synthesis of Lactam Analogues of the Epothilone</p>				

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
<p>Natural Products" <i>J. Am. Chem. Soc.</i> 122(37):8890-8897, 2000.</p> <p>Broker <i>et al.</i>, "Late Activation of Apoptotic Pathways Plays a Negligible Role in Mediating the Cytotoxic Effects of Disodermolide and Epothilone B in Non-Small Cell Lung Cancer Cells" <i>Cancer Research</i> 62(14):4081-4088, 2002.</p> <p>Brummond <i>et al.</i>, "A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio- and Stereoselective Synthesis of Lactam Analogues of the Epothilone Natural Products" <i>Chemtracts</i> 14(7):401-404, 2001.</p> <p>Carlomagno <i>et al.</i>, "The High-Resolution Solution Structure of Epothilone A Bound to Rubulin: An Understanding of the Structure-Activity Relationships for a Powerful Class of Antitumor Agents" <i>Angew. Chem. Int. Ed.</i> 42:2511-2515, 2003.</p> <p>Carlomagno <i>et al.</i>, "Derivation of Dihedral Angles from Ch-Ch Dipolar-Dipolar Cross-Correlated Relaxation Rates: A C-C Torsion Involving a Quaternary Carbon Atom in Epothilone A Bound to Tubulin" <i>Angew. Chem. Int. Ed.</i> 42:2515-2517, 2003.</p> <p>Carreira, "Discovery and Study of New Reaction Chemistry: Applications in Complex Molecule Assembly" <i>Chimia</i> 55(10):818-820, 2001.</p> <p>Casas <i>et al.</i>, "BINOLAM, a Recoverable Chiral Ligand for Bifunctional Enantioselective Catalysis: The Asymmetric Synthesis of Cyanohydrins" <i>Organic Letters</i> 4(15):2589-2592, 2002.</p> <p>Chakravarty <i>et al.</i>, "Taxoid and Non-Taxoid Inhibitors of Microtubule Disassembly: Molecular Modeling Approach to Elucidation of a Common Pharmacophore" Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, September 7-11, MEDI-075. <i>American Chemical Society</i>.</p> <p>Chappell <i>et al.</i>, "En Route to a Plant Scale Synthesis of the Promising Antitumor Agent 12,13-Desoxyepothilone B" <i>Org. Letter.</i> 2(11):1633-1636, 2000.</p> <p>Chen <i>et al.</i>, "Epothilone Biosynthesis: Assembly of the Methylthiazolylcarboxy Starter Unit on the EpoB Subunit" <i>Chem. Biol.</i> 8(9):899-912, 2001.</p> <p>Chou <i>et al.</i>, "Quantitative Analysis of Dose-Effect Relationships The Combined Effects of Multiple Drugs or Enzyme Inhibitors" <i>Adv. Enzyme Reg.</i> 22:27-55, 1984.</p> <p>Chou, "Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel" <i>Proc. Natl. Acad. Sci. USA</i> 95:15798-15802, 1998.</p> <p>Chou <i>et al.</i>, "The Synthesis, Discovery, and Development of a Highly Promising Class of Microtubule Stabilization Agents: Curative Effects of Desoxyepothilones B and F Against Human Tumor Xenografts in Nude Mice" <i>Proc. Natl. Acad. Sci. USA</i> 98(14):8113-8118, 2001.</p> <p>Chou <i>et al.</i>, "Desoxyepothilone B: An Efficacious Microtubule-Targeted Antitumor Agent with a Promising In Vivo Profile Relative to Epothione B" <i>Proc. Natl. Acad. Sci. USA</i> 95:9642-9647, 1998.</p> <p>Chou <i>et al.</i>, "Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B" <i>Proc. Natl. Acad. Sci. USA</i> 95:9642-9647, 1998.</p>				

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	Chou <i>et al.</i> , "Design and Total Synthesis of a Superior Family of Epothiolone Analogues, which Eliminate Xenograft Tumors to a Nonrelapsable State" <i>Angew. Chem. Int. Ed. Engl.</i> 42 :4762-4767, 2003.			
	Corey <i>et al.</i> , "Chemistry of Diimide. Some New Systems for the Hydrogenation of Multiple Bonds" <i>Tet. Lett.</i> 11 :347-352, 1961.			
	Correia <i>et al.</i> , "Physiochemical Aspects of Tubulin-Interacting Antimitotic Drugs" <i>Curr. Pharm. Des.</i> 7 (13):1213-1228, 2001.			
	Cowden <i>et al.</i> , "Cancer Drugs-Better than Taxol?" <i>Nature</i> 387 :238-239, 1997.			
	De Brabander <i>et al.</i> , "Towards a Synthesis of Epothilone: A Rapid Assembly of the C(1)-C(6) and C(7)-C(12) Fragments" <i>Synlett.</i> 7 :824-826, 1997.			
	Delbaldo <i>et al.</i> , "Nouveaux medicamenets dans le cancer bronchique" <i>La Presse Medicate</i> 31 :802-809, 2002.			
	Denmark <i>et al.</i> , "Cyclopropanation with Diazomethane and Bis(Oxazoline) Palladium(II) Complexes" <i>J. Org. Chem.</i> 62 :3375-3389, 1997.			
	Duthaler <i>et al.</i> , "Enantioselective Aldol Reaction of Tert-Butyl Acetate Using Titanium-Carbohydrate Complexes" <i>Angew. Chem. Int. Ed. Engl.</i> 28 :495-497, 1989.			
	Ermolenko <i>et al.</i> , "Synthesis of Epothilones B and D from D-Glucose" <i>Tet. Lett.</i> 43 :2895-2898, 2002.			
	Essayan <i>et al.</i> , "Successful Parenteral Desensitization to Paclitaxel" <i>J. Allergy Clin. Immunol.</i> 97 :42-46, 1996.			
	Fletcher <i>et al.</i> , "Structure of the Mitogen-Inducible TIS10 Gene and Demonstration That the TIS10-Encoded Protein Is a Functional Prostaglandin G/H Synthase" <i>J. Biol. Chem.</i> 267 :4338-4344, 1992.			
	Florsheimer <i>et al.</i> , "Epothilones and Their Analogues-A New Class of Promising Microtubule Inhibitors" <i>Expert Opin. Ther. Pat.</i> , 11 (6):951-968, 2001.			
	Frykman <i>et al.</i> , "Control of Secondary Metabolite Congener Distributions via Modulation of the Dissolved Oxygen Tension" <i>Biotechnol. Prog.</i> 18 :913-920, 2002.			
	Fürstner, "Olefin Metathesis and Beyond" <i>Angew. Chem. Int. Ed. Engl.</i> 39 :3013-3043, 2000.			
	Fürstner <i>et al.</i> , "Concise Total Syntheses of Epothilone A and C Based on Alkyne Metathesis" <i>Chem. Commun.</i> 12 :1057-1059, 2001.			
	Geng <i>et al.</i> , "Design and Synthesis of De Novo Macrocyclic Hybrids as Potential Anticancer Agents" <i>Abstr. Pap.-Am. Chem. Soc.</i> , 221st , MEDI-130, 2001.			
	Georg <i>et al.</i> , "Studies Toward the Synthesis of Epothilone Affinity Labels" <i>Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, MEDI-075</i> , 2000.			
	Gerlach <i>et al.</i> , "Synthesis of the C(7)-C(17) Segment of Epothilones by a 10-Membered Ring Closing Metathesis Reaction" <i>Synlett.</i> 10 :1108-1110, 1998.			
	Gerth. <i>et al.</i> , "Studies on the Biosynthesis of Epothilones: the PKS and Epothilone C/D Monooxygenase" <i>J. Antibiot.</i> , 54 (2):144-148, 2001.			
	Gerth <i>et al.</i> , "Epothilons A and B: Antifungal and Cytotoxic Compounds from Sorangium			

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	cellulosum (Myxobacteria) Production, Physico-chemical and Biological Properties" <i>J. Antibiotics</i> :49-53, 1996.			
	Gerth <i>et al.</i> , "Studies on the Biosynthesis of Epothilones: The Biosynthetic Origin of the Carbon Skeleton" <i>J. Antibiot.</i> 53 (12):1373-1377, 2000.			
	Giannakakou, et al., "A Common Pharmacophore for Epothilone and Taxanes: A Molecular Basis for Drug Resistance Conferred by Tubulin Mutations in Human Cancer Cells" <i>Proc. Natl. Acad. Sci.</i> , 97 (6): 2904-2909, 2000.			
	Griffin, et al., "Molecular Determinants of Epothilone B Derivative (BMS 247550) and Apo-2L/TRAIL-induced Apoptosis of Human Ovarian Cancer Cells", <i>Gynecologic Oncology</i> , 89 : 37-47, 2003.			
	Grubbs, et al., "Ring-Closing Metathesis and Related Processes in Organic Synthesis" <i>Acc. Chem. Res.</i> 28 :446-452, 1995.			
	Gupta, et al., Understanding Tubulin-Taxol Interactions: Mutations That Impart Taxol Binding to Yeast Tubulin <i>PNAS</i> , 100 : 5394-6397, 2003.			
	Haar, et al., "Discodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol", <i>Biochemistry</i> , 35 : 243-250, 1996.			
	Hardt, et al., "New Natural Epothilones from Sorangium Cellulosum, Strains So ce90/B2 and So ce90/D13: Isolation, Structure Elucidation and SAR Studies" <i>J. Nat. Prod.</i> , 64 (7): 847-856, 2001.			
	Harris, et al., Complex Target-Oriented Synthesis in the Drug Discovery Process: A Case History in the dEpoB Series <i>J. Org. Chem.</i> , 64 :9434-8456, 1999.			
	Harris, et al., New Chemical Synthesis of the Promising Cancer Chemotherapeutic Agent 12, 13-Desoxyepothilone B: Discovery of a Surprising Long-Range Effect on the Diastereoselectivity of an Aldol Condensation <i>J. Am. Chem. Soc.</i> , 121 : 7050-7062, 1999.			
	Harris, et al., "Chemical Synthesis and Biological Studies of the Epothilones – Microtubule Stabilizing Agents with Enhanced Activity Against Multidrug-Resistant Cell Lines and Tumors", <i>Chemistry for the 21st Century</i> , 8-36, 2001.			
	Hayward, et al. "Total Synthesis of Rapamycin via a Novel Titanium-Mediated Aldol Macrocyclization Reaction", <i>J. Am. Chem. Soc.</i> , 115 : 9345-9346, 1993.			
	He, et al.. "Novel Molecules that Interact with Microtubules and have Functional Activity Similar to Taxol" <i>Drug Discovery Today</i> , 6 (22): 1153-1164,2001.			
	He, Yun et al., "Total Synthesis and Biological Evaluation of Epothilones" The Scripps Research Institute Order No.: DA9966202 From: Diss. Abstr. Int., B 2000, 61 (3), 1414, 2000			
	Hofle, et al., "Epothilone A-D and Their Thiazole-Modified Analogs as Novel Anticancer Agents" <i>Pure Appl. Chem.</i> , 71 :2019-2024, 1999.			
	Hofle, et al., "N-Oxidation of Epothilone A-C and O-Acyl Rearrangement to C-19 and C-21			

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
<p>Substituted Epothilones" <i>Angew. Chem. Int. Ed.</i>, 38(13/14):1971-1974, 1999.</p> <p>Holland, et al., "Design, Synthesis and Biological Evaluation of Epothilone Analogs", Book of Abstracts, 215th ACS National Meeting, Dallas, March 29-April 2, ORGN-015.</p> <p>Ivin, "Some Recent Applications of Olefin Metathesis in Organic Synthesis: A Review", <i>J. Mol. Catal. A: Chem.</i>, 133(1-2): 1998</p> <p>Julien, et al., "Isolation and Characterization of the Epothilone Biosynthetic Gene Cluster from Sorangium Cellulosum" <i>Gene</i>, 249(1-2): 153-160, 2000.</p> <p>Kalesse, et al., "The Formal Total Synthesis of Epothilone A" <i>Eur. J. Org. Chem.</i>, 11: 2817-2823, 1999.</p> <p>Koch, et al., Diastereoselective Titanium Enolate Aldol Reaction for the Total Synthesis of Epothilones <i>Organic Letters</i>, 2(22): 3811-3814, 2002.</p> <p>Lee, et al., "BMS-247550: A Novel Epothilone Analog with a Mode of Action Similar to Paclitaxel but Possessing Superior Antitumor Efficacy" <i>Clin. Cancer Res.</i>, 7(5): 1429-1437, 2001.</p> <p>Lee, et al., "Synthesis of the C11-C21 and C13-C21 Fragments of Epothilones from D-glucose" <i>Bull. Korean Chem. Soc.</i>, 21(12): 1177-1178, 2000.</p> <p>Lee, et al., "Synthesis Toward Epothilone A: A Coupling Reaction Between the Sulfone of C1-C10 and the Allylic Bromide of C11-C21" <i>Bull. Korean Chem. Soc.</i>, 20(4): 403-404, 1999.</p> <p>Lee, et al., "Insights into Long-Range Structural Effects on the Stereochemistry of Aldol Condensations: A Practical Total Synthesis of Deoxyepothilone F" <i>J. Am. Chem. Soc.</i> 123: 5249-5259, 2001.</p> <p>Lee, et al., "Total Synthesis and Antitumor Activity of 12,13-Desoxyepothilone F: An Unexpected Solvolysis Problem at C15, Mediated by Remote Substitution at C21" <i>J. Org. Chem.</i>, 65: 6525-6533, 2000.</p> <p>Levin, et al., "An Alternative Procedure for the Aluminum-Mediated Conversion of Esters to Amides", <i>Synth. Commun.</i> 12: 989, 1982.</p> <p>Li, et al., "Synthesis of a Novel Epothilone B Analog as a Potential Photoaffinity Label" <i>Abstr. Pap.-Am. Chem. Soc. 221st MEDI-137</i>, 2001</p> <p>Li, et al., "Process Development of the Semisynthesis of a Biologically Active Epothilone Analogue" <i>Abstracts of Papers, 222nd ACS National Meeting, Chicago, IL, August 26-30, ORGN-238</i>, 2001.</p> <p>Li, et al., "Antimitotic Agents" <i>Annu. Rep. Med. Chem.</i>, 34: 139-148, 1999.</p> <p>Lichtner <i>et al.</i>, "Subcellular Distribution of Epothilones in Human Tumor Cells" <i>Proc. Natl. Acad. Sci. U.S.A.</i>, 98(20): 11743-11748, 2001.</p> <p>Lin, et al., "Design, Synthesis and SAR of Novel Hybrid Constructs Based on the Common Pharmacophore for Microtubule-Stabilizing Agents" <i>Book of Abstracts, 217th ACS National meeting, Anaheim, CA, March 21-25, MEDI-038</i>, 1999.</p> <p>Lin, et al., "Design and Synthesis of Taxoid-Epothilone Hybrids" <i>Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27, ORGN-464</i>.</p>				

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	Lindel, et al., "Eleutherobin, A New Cytotoxin that Mimics Paclitaxel (Taxol) by Stabilizing Microtubules", <i>J. Am. Chem. Soc.</i> 119 : 8744-8745, 1997.			
	List, et al., "Proline-Catalyzed Direct Asymmetric Aldol Reactions" <i>J. Am. Chem. Soc.</i> 122 : 2395-2396, 2000.			
	Liu, et al., "Total Synthesis of Epothilone A through Stereospecific Epoxidation of the p-Methoxybenzyl Ether of Epothilone C" <i>Chem. Eur. J.</i> , 8 (16): 3747-3756, 2002.			
	Liu, et al., "Epoxide Opening with Acetylide for Synthesis of Epothilone A C7-21 Segment", <i>Tetrahedron Lett.</i> 39 (29): 5261-5264, 1998.			
	Liu et al., "Chiral Synthesis of the C ₃ -13 Segment of Epothilone A" <i>Synlett Letters</i> 1383-84 (1997)			
	Lythgoe, et al., "Allylic Phosphine Oxides as Precursors of Dienes of Defined Geometry: Synthesis of 3-Deoxyvitamin D ₂ ", <i>Tetrahedron Lett.</i> 40 :3863-3866, 1975.			
	Machajewski, et al., "Chemoenzymic Synthesis of Key Epothilone Fragments" <i>Synthesis (Spec. Iss.)</i> , 1469-1472, 1999.			
	Martin, et al.. "The 12,13-diol Cyclization Approach for a Truly Stereocontrolled Total Synthesis of Epothilone B and the Synthesis of a Conformationally Restrained Analog" <i>Chem. Eur. J.</i> , 42 (47): 8373-8377, 2001.			
	Martin, "How Stable are Epoxides? A Novel Synthesis of Epothilone B" <i>Angew. Chem. Int. Ed.</i> , 39 (3): 581-583, 2000.			
	May, et al., "Total Synthesis of (-) Epothilone B", <i>Chem. Commun.</i> , 95 : 1369-1374, 1998.			
	McDaid <i>et al.</i> , "Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, During a Phase I Clinical Study" <i>Clinical Cancer Research</i> 8 :2035-2043, 2002.			
	Meng et al. "Total Synthesis of Epothilones A and B" <i>J. Am. Chem. Soc.</i> 119 :42 10073-10092 (1997).			
	Meng et al. "Studies toward a Synthesis of Epothilone A: Use of Hydroxyran Templates for the Management of Acyclic Stereochemical Relationships" <i>J. Org. Chem.</i> 61 :23 7998-8001 (1996).			
	Moasser et al., "Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol...." <i>Proc. Natl. Acad. Sci. USA</i> , 95 :1369-1374 (1998).			
	Molnar, et al., "The Biosynthetic Gene Cluster for the Microtubule-Stabilizing Agents Epothilones A and B from <i>Sorangium Cellulosum</i> So ce90" <i>Chem. Biol.</i> , 7 (2): 97-109, 2000.			
	Mooberry, et al., "Laulimalide and Isolaulimalide, New Paclitaxel-Like Microtubule-Stabilizing Agents", <i>Cancer Res.</i> 59 : 653-680, 1999.			
	Morrissey, et al., <i>J. Am. Chem. Soc.</i> 107 : 4346, 1985.			
	Mulzer, et al., "Total Syntheses of Epothilones B and D" <i>J. Org. Chem.</i> , 65 (22); 7456-7467, 2000.			
	Mulzer, et al., "A Novel Highly Stereoselective Total Synthesis of Epothilone B and of its (12R,13R) Acetonide" <i>Tetrahedron Lett.</i> , 41 (40):7635-7638, 2000.			

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
<p>Mulzer, et al., "Synthesis of the C(11)-C(20) Segment of the Cytotoxic Macrolide Epothilone B", <i>Tetrahedron Letters</i>, 38(44):7725-7728, 1997.</p> <p>Mulzer, et al., "Easy Access to the Epothilone Family-Synthesis of Epothilone B", <i>Tetrahedron Letters</i>, 39(47): 8633-8636, 1998.</p> <p>Mulzer, "Progress in the Synthesis of Chiral Heterocyclic Natural Products: Epothilone B and Tartrolon B" <i>J. Heterocycl. Chem.</i>, 36(6): 1421-1436, 1999.</p> <p>Nagaoka, et al., "Further Synthetic Studies on Rifamycin S", <i>Tetrahedron</i>, 37: 3873-3888, 1981.</p> <p>Nahm, et al., "N-Methoxy-N-Methylamides as Effective Acylating Agents", <i>Tetrahedron Lett.</i> 22: 3815-3818, 1981.</p> <p>Nakamura, S., "Total Synthesis of Antitumor Antibiotic Epothilone Having Same Mechanism of Action with Taxol", <i>Kagaku (Kyoto)</i>", (In Japanese) 52(7): 70-71, 1997.</p> <p>Newman, et al., "Antitumor Efficacy of 26-Fluoroepothilone B Against Human Prostate Cancer Xenografts" <i>Cancer Chemother. Pharmacol.</i>, 48(4): 319-326, 2001.</p> <p>Nicolaou, et al., "Synthesis and Biological Evaluation of 12, 13-cyclopropyl and 12,13-cyclobutyl Epothilones" <i>ChemBioChem (Angew. Chem. Int. Ed. Engl.)</i>, 2(1): 69-75, 2001.</p> <p>Nicolaou, et al., "Recent Developments in the Chemistry, Biology and Medicine of the Epothilones" <i>Chem. Commun.</i>, 17:1523-1535, 2001.</p> <p>Nicolaou, et al. "Chemical Synthesis and Biological Evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl Epothilones and Related Pyridine Side Chain Analogues" <i>J. Am. Chem. Soc.</i>, 123(38): 9313-9323, 2001.</p> <p>Nicolaou, et al., "Synthesis of 16-desmethyllepothilone B: Improved Methodology for the Rapid, Highly Selective and Convergent Construction of Epothilone B and Analogs" <i>Chem. Commun.</i>, 6:519-520, 1999.</p> <p>Nicolaou, et al., "Total Synthesis of 16-Desmethyllepothilone B, Epothilone B10, Epothilone F, and Related Side Chain Modified Epothilone B Analogues", <i>Chem. Eur. J.</i>, 6(15): 2783-2800, 2000.</p> <p>Nicolaou, et al., "Chemical Synthesis and Biological Properties of Pyridine Epothilones" <i>Chem. Biol.</i> 7(8): 593-599, 2000.</p> <p>Nicolaou, et al., "Chemistry, Biology and Medicine of Selected Tubulin Polymerizing Agents" <i>Pure Appl. Chem.</i>, 71(6): 989-997, 1999.</p> <p>Nicolaou et al. "Synthesis and Biological Properties of C12,13-Cyclopropyl-Epothilone A and Related Epothilones" <i>Chem. Biol.</i>, 5(7): 365-372, 1998</p> <p>Nicolaou, et al., "Total Synthesis of Epothilone E and Related Side-Chain Modified Analogues via a Stille Coupling Based Strategy" <i>Bioorg. Med. Chem.</i>, 7(5):665-697, 1999.</p> <p>Nicolaou, et al., Chemie und Biologie der Epothilone, <i>Agnew. Chem.</i>, 110: 2120-2153, 1998.</p> <p>Nicolaou, et al., "Chemistry and Biology of Taxol", <i>Angew. Chem. Int. Ed. Engl.</i> 33: 15-44, 1994.</p> <p>Nicolaou, K.C. et al. "Total Synthesis of Epothilone E and Analogues with Modified Side</p>				

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
<p>Chains through the Stille Coupling Reaction" <i>Angew. Chem. Int. Ed.</i>, 37: 84-87 (1998).</p> <p>Nicolaou, et al., "Ring-Closing Metathesis in the Synthesis of Epothilones and Polyether Natural Products" <i>Top. Organomet. Chem. 1 (Alkene Metathesis in Organic Synthesis)</i> 1: 73-104, 1998.</p> <p>Nicolaou, K.C. et al., "Total Synthesis of 26-Hydroxy-Epothilone B and Related Analogs via a Macrolactonization Based Strategy" <i>Tetrahedron</i> 54: 7127-7166 (1998).</p> <p>Nicolaou, et al., "Synthesis of Epothilones: A and B in Solid and Solution Phase", <i>Nature</i>, 390: 100, 1997.</p> <p>Njardarson, et al., "Discovery of Potent Cell Migration Inhibitors Through Total Synthesis: Lessons from Structure – Activity Studies of (+)- Migrastatin", <i>J. Am. Chem. Soc.</i> 126:1038-1040, 2004.</p> <p>Njardarson, et al., Application of hitherto unexplored macrocyclization strategies in the epothilone series: novel epothilone analogs by total synthesis, <i>Chem. Commun.</i>, 2759-2761, 2002.</p> <p>Noyori, et al., "Asymmetric Hydrogenation of β-Keto Carboxylic Esters. A Practical, Purely Chemical Access to β-Hydroxy Esters in High Enantiomeric Purity" <i>J. Am. Chem. Soc.</i> 109: 5856-5859, 1987.</p> <p>Ojima, et al., "New-Generation Taxoids and Hybrids of Microtubule-Stabilizing Anticancer Agents" <i>Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, ORGN-245</i>, 2000.</p> <p>Ojima, et al., "A Common Pharamcophore for Cytotoxic Natural Products that Stabilize Microtubules <i>Proc. Natl. Acad. Sci. U.S.A.</i>, 96: 4256-4261, 1999.</p> <p>Ojima, et al., "Enantiopure Fluorine-Containing Taxoids: Potent Anticancer Agents and Versatile Probes for Biomedical Problems", <i>J. Fluorine Chem.</i> 97:3-10, 1999.</p> <p>Panicker <i>et al.</i>, "An unusual Reversal of Stereoselectivity in a Boron Mediated Aldol Reaction: Enantioselective Synthesis of the C1-C6 Segment of the Epothilones" <i>Tetrahedron</i>, 56(40): 7859-7868, 2000.</p> <p>Paterson <i>et al.</i>, "Stereocontrolled Aldol Additions to α-Methylene-β-Alkoxy Aldehydes: Application to the Synthesis of a C₁₃-C₂₅ Segment of Bafilomycin A₁" <i>Tetrahedron Lett.</i> 36:175-178, 1995.</p> <p>Petrache <i>et al.</i>, "The Role of the Microtubules in Tumor Necrosis Factor-a-Induced Endothelial Cell Permeability" <i>Am. J. Respir. Cell Mol. Biol.</i> 28:574-581, 2003.</p> <p>Pettet <i>et al.</i>, "Isolation and Structure of the Cancer Cell Growth Inhibitor Dictyostatin 1", <i>J. Chem. Soc. Chem. Commun.</i> 1111-1112, 1994.</p> <p>Pradella <i>et al.</i>, "Characterisation, Genome Size and Genetic Manipulation of the Myxobacterium Sorangium Cellulosum So ce56" <i>Archives of Microbiology</i> 1-17, 2002.</p> <p>Pryor <i>et al.</i>, "The Microtubule Stabilizing Agent Laulimalide Does Not Bind in the Taxoid Site, Kills Cells Resistant to Paclitaxel and Epothilones, and May Not Require Its Epoxide Moiety for Activity" <i>Biochemistry</i> 41:9109-9115, 2002.</p>				

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
<p>Quitschalle <i>et al.</i>, "Improved Synthesis of the Northern Hemisphere of Epothilone A by a Sharpless Asymmetric Dihydroxylation" <i>Tetrahedron Letters</i>. 40(44):7765-7768, 1999.</p> <p>Regentin <i>et al.</i>, "Development of a Cost Effective Epothilone D Process in <i>Myxococcus Xanthus</i>" <i>Abstr. Pap-Am. Chem. Soc.</i> 221st, BIOT-061, 2001.</p> <p>Regentin <i>et al.</i>, "Nutrient Regulation of Epothilone Biosynthesis in Heterologous and Native Production Strains" <i>Appl. Microbiol. Biotechnol.</i> 61:451-455, 2003.</p> <p>Regueiro-Ren <i>et al.</i>, "Synthesis and Biological Activity of Novel Epothilone Aziridines" <i>Org. Lett.</i> 3(17): 2693-2696, 2001.</p> <p>Regueiro-Ren <i>et al.</i>, SAR and pH Stability of Cyano-Substituted Epothilones, <i>Organic Letters</i>, 4(22): 3815-3818, 2002.</p> <p>Reiff <i>et al.</i>, "Progress Toward Total Syntheses of Epothilones A and B" <i>Book of Abstracts, 215th ACS National Meeting, Dallas, March 29-April 2, ORGN-086</i></p> <p>Rivkin, <i>et al.</i>, "Complex Target-Oriented Total Synthesis in the Drug Discovery Process: The Discovery of a Highly Promising Family of Second Generation Epothilones" <i>J. Am. Chem. Soc.</i> 125:2899-2901, 2003.</p> <p>Rivkin <i>et al.</i>, "Total Syntheses of [17]- and [18] Dehydrodesoxyepothilones B via a Concise Ring-Closing Metathesis-Based Strategy: Correlation of Ring Size with Biological Activity in the Epothilone Series" <i>J. Org. Chem.</i>, 67:7737-7740, 2002.</p> <p>Rivkin <i>et al.</i>, "On the Introduction of a Trifluoromethyl Substituent in the Epothilone Setting: Chemical Issues Related to Ring Forming Olefin Metathesis and Earliest Biological Findings" <i>Organic Letters</i>, 4(23):4081-4084, 2002.</p> <p>Roush <i>et al.</i>, "Acyclic Diastereoselective Synthesis Using Tartrate Ester Modified Crotylboronates. Double Asymmetric Reactions with α-Methyl Chiral Aldehydes and Synthesis of the C(19)-C(29) Segment of Rifamycin S" <i>J. Am. Chem. Soc.</i> 112:6348-6359, 1990.</p> <p>Santi <i>et al.</i>, "An Approach for Obtaining Perfect Hybridization Probes for Unknown Polyketide Synthase Genes: A Search for the Epothilone Gene Cluster" <i>Gene</i>, 247(1-2): 97-102, 2000.</p> <p>Sawada <i>et al.</i>, "Enantioselective Total Synthesis of Epothilone A Using Multifunctional Asymmetric Catalysis" <i>Angew. Chem. Int. Ed.</i> 39(1):209-213, 2000.</p> <p>Sawada <i>et al.</i>, "Enantioselective Total Synthesis of Epothilones A and B Using Multifunctional Asymmetric Catalysis" <i>J. Am. Chem. Soc.</i> 122(43):10521-10532, 2000.</p> <p>Schiff <i>et al.</i>, "Promotion of Microtubule Assembly <i>in vitro</i> by Taxol" <i>Nature</i>, 277:665-667, 1979.</p> <p>Scholl <i>et al.</i>, "Increased Ring Closing Metathesis Activity of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with Imidazolin-2-Ylidene Ligands", <i>Tetrahedron Lett.</i> 40:2247-2250, 1999</p> <p>Schrock, "Olefin Metathesis by Well-Defined Complexes of Molybdenum and Tungsten" <i>Top. Organomet. Chem.</i> 1:1-36, 1998.</p>				

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	Scudiero <i>et al.</i> , "Evaluation of a Soluble Tetrazolium/Formazan Assay for Cell Growth and Drug Sensitivity in Culture Using Human and Other Tumor Cell Lines", <i>Cancer Res.</i> 48 :4827-4833, 1988.			
	Sefkow <i>et al.</i> , "Derivatization of the C12-C13 Functional Groups of Epothilones A, B, and C" <i>Bioorg. Med. Chem.</i> 8 :3031-3036, 1998.			
	Sefkow <i>et al.</i> , "Oxidative and Reductive Transformations of Epothilone A" <i>Bioorg. Med. Chem.</i> 8 (21):3025-3030, 1998.			
	Sefkow <i>et al.</i> , "Substitutions at the Thiazole Moiety of Epothilone" <i>Heterocycles</i> , 48 (12):2485-2488, 1998.			
	Schinzer <i>et al.</i> , "Total Synthesis of (-)-epothilone A" <i>Chem.-Eur. J.</i> , 5 (9):2483-2491, 1999.			
	Schinzer <i>et al.</i> , "Total Synthesis of (-)-epothilone B" <i>Chem.-Eur. J.</i> , 5 (9):2492-2500, 1999.			
	Schneider <i>et al.</i> , "Utilization of Alternate Substrates by the First Three Modules of the Epothilone Synthetase Assembly Line" <i>J. Am. Chem. Soc.</i> 124 :11272-11273, 2002.			
	Scholl <i>et al.</i> , "Increased Ring Closing Metathesis Activity of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with Imidazolin-2-Ylidene Ligands" <i>Tetrahedron Lett.</i> 40 :2247, 1999.			
	Scudiero <i>et al.</i> , "Evaluation of a Soluble Tetrazolium/Formazan Assay for Cell Growth and Drug Sensitivity in Culture Using Human and Other Tumor Cell Lines" <i>Cancer Research</i> 48 :4827-4833, 1988.			
	Shibasaki <i>et al.</i> , "Multifunctional Asymmetric Catalysis" <i>Chem. Pharm. Bull.</i> , 49 (5):511-524, 2001.			
	Shioji <i>et al.</i> , "Synthesis of C1-C6 Fragment for Epothilone A via Lipase-Catalyzed Optical Resolution" <i>Synth. Commun.</i> , 31 (23):3569-3575, 2001.			
	Sinha, <i>et al.</i> , "The Antibody Catalysis Route to the Total Synthesis of Epothilones" <i>Proc. Natl. Acad. Sci.</i> 95 (25):14603-14608, 1998.			
	Sinha, <i>et al.</i> , "Catalytic Antibody Route to the Naturally Occurring Epothilones: Total Synthesis of Epothilones A-F" <i>Chem. Eur. J.</i> 7 (8):1691-1702, 2001.			
	Sinha <i>et al.</i> , "Total Synthesis of Epothilones and Some 14-Fluoroanalogs via Antibody Catalysis" <i>Book of Abstracts, 217th ACS National Meeting, Anaheim, CA, March 21-25, ORGN-054</i>			
	Sinha <i>et al.</i> , "Synthesis of Epothilone Analogues by Antibody-Catalyzed Resolution of Thiazole Aldol Synthons on a Multigram Scale. Biological Consequences of C-13 Alkylation of Epothilones" <i>Chem. Bio. Chem.</i> , 2 (9):656-665, 2001.			
	Sinha <i>et al.</i> , "Sets of Aldolase Antibodies with Antipodal Reactivities. Formal Synthesis of Epothilone E by Large Scale Antibody-Catalyzed Resolution of Thiazole Aldol" <i>Org. Lett.</i> , 1 (10):1623-1626, 1999.			
	Sinha <i>et al.</i> , "Regioselective Synthesis of Fluoro Aldols. Studies Toward Fluro Epothilones Syntheses via Antibody Catalysis" <i>Tetrahedron Letters</i> , 41 (43):8243-8246, 2000.			
	Skehan <i>et al.</i> , "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening" <i>Journal</i>			

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
<p><i>of the National Cancer Institute, 82:1107-1112, 1990.</i></p> <p>Smart, "Fluorine Substituent Effects (on bioactivity)" <i>Journal of Fluorine Chemistry</i>, 109:3-11, 2001.</p> <p>Stachel <i>et al.</i>, "The Epothilones, Eleutherobins, and Related Types of Molecules" <i>Curr. Pharm. Des.</i> 7(13):1277-1290, 2001.</p> <p>Stachel <i>et al.</i>, "On the Interactivity of Complex Synthesis and Tumor Pharmacology in the Drug Discovery Process: Total Synthesis and Comparative in Vivo Evaluations of the 15-Aza Epothilones" <i>J. Org. Chem.</i> 66:4369-4378, 2001.</p> <p>Su <i>et al.</i>, "Structure-Activity Relationships of the Epothilones and the First In Vivo Comparison with Paclitaxel" <i>Angew. Chem. Int. Ed. Engl.</i> 36:2093-2096, 1997.</p> <p>Su <i>et al.</i>, "Total Synthesis of (-) Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure-Activity Relationships of the Epothilones", <i>Angew. Chem. Int. Ed. Engl.</i> 36:757-759, 1997.</p> <p>Sun <i>et al.</i> "Stereoselective Total Synthesis of Epothilones by the Metathesis Approach involving C9-C10 Bond Formation" <i>Angew. Chem. Int. Ed.</i> 8:1381-1383, 2002.</p> <p>Tang <i>et al.</i>, "Cloning and Expression of the Epothilone Gene Cluster" <i>Science</i>, 287:640-642, 2000.</p> <p>Tang <i>et al.</i>, "Generation of Novel Epothilone Analogs with Cytotoxic Activity by Biotransformation" <i>The Journal of Antibiotics</i>, 56:16-23, 2003.</p> <p>Tanimori <i>et al.</i>, "Simple Synthesis of Both Enantiomers of the C7-C12 Segment of Epothilones" <i>Biosci. Biotechnol. Biochem.</i>, 62(12):2428-2430, 1998.</p> <p>Tanimori <i>et al.</i>, "Easy Access to Both Enantiomers of C7-C12 Segment of Epothilones" <i>Synth. Commun.</i> 29(24): 4353-4360, 1999.</p> <p>Taylor <i>et al.</i>, "Total Synthesis of Epothilones B and D" <i>Org. Lett.</i> 3(14):2221-2224, 2001.</p> <p>Taylor <i>et al.</i>, "The Identification of the Biologically Active Conformation of Epothilone" <i>Book of Abstracts, 217th ACS National Meeting, Anaheim, CA, March 21-25, ORGN-041</i></p> <p>Taylor <i>et al.</i>, "The Conformational Properties of Epothilone"-Erratum <i>J. Org. Chem.</i>, 65(17):5449, 2000.</p> <p>Taylor <i>et al.</i>, "Conformational Properties of Epothilone" <i>J. Org. Chem.</i> 64(19):7224-7228, 1999.</p> <p>Taylor <i>et al.</i>, "Catalytic Diastereoselective Reductive Aldol Reaction: Optimization of Interdependent Reaction Variables by Arrayed Catalyst Evaluation" <i>J. Am. Chem. Soc.</i> 121:12202-12203, 1999.</p> <p>Taylor, "A Formal Total Synthesis of Epothilone A: Enantioselective Preparation of the C1-C6 and C7-C12 Fragments" <i>J. Org. Chem.</i> 63(25):9580-9583, 1998.</p> <p>Toh <i>et al.</i>, "Studies on a Convergent Route to Side-Chain Analogues of Vitamin D: 25-Hydroxy-23-Oxavitamin D₃" <i>J. Org. Chem.</i> 48:1414-1417, 1983.</p> <p>Trnka <i>et al.</i>, "The Development of L₂X₂Ru=CHR Olefin Metathesis Catalysts: An Organometallic Success Story" <i>Acc. Chem. Res.</i> 34:18-31, 2001.</p>				

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	Trnka <i>et al.</i> , "The Development of L ₂ X ₂ Ru=CHR Olefin Metathesis Catalysts: An Organometallic Success Story" <i>Acc. Chem. Res.</i> 34 :18-29, 2001.			
	Tsuji <i>et al.</i> , "Alterations in Cellular Adhesion and Apoptosis in Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase 2", <i>Cell</i> , 3 :493, 1995.			
	Valluri <i>et al.</i> , "Total Synthesis of Epothilone B" <i>Org. Lett.</i> , 3 (23):3607-3609, 2001.			
	Victory <i>et al.</i> , "Development of an Epothilone Pharmacophore" <i>Book of Abstracts, 215th ACS National Meeting, Dallas, March 29-April 2, MEDI-187</i>			
	Von Angerer, "Tubulin as a Target for Anticancer Drugs" <i>Curr. Opin. Drug Discovery Dev.</i> 3 (5):575-584, 2000.			
	Wessjohann <i>et al.</i> , "Synthesis of Natural-Product-Based Compound Libraries" <i>Curr. Opin. Chem. Biol.</i> 4 :303-309, 2000.			
	Wessjohann <i>et al.</i> , "Synthetic Access to Epothilones-Natural Products with Extraordinary Anticancer Activity" <i>Org. Synth. Highlights IV Ed:</i> Schmalz, H., Wiley-VCH Verlag GmbH: Weinheim Germany, 251-267, 2000.			
	White <i>et al.</i> , "Total Synthesis of Epothilone B, Epothilone D, and cis- and trans-9,10-Dehydroepothilone D" <i>J. Am. Chem. Soc.</i> , 123 (23):5407-5413, 2001.			
	White <i>et al.</i> , Total Synthesis of Epothilone B, Epothilone D, and cis-and trans-9, 10-Dehydroepothilone D, <i>J. Am. Chem. Soc.</i> , 125 :3190, 2003, Additions and Corrections.			
	White, et al., "Synthetic Approach Towards the Total Synthesis of Epothilone B" <i>Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27, ORGN-041</i>			
	White, et al., "A Highly Stereoselective Synthesis of Epothilone B" <i>J. Org. Chem.</i> , 64 (3):684-685, 1999.			
	White, et al., "Improved Synthesis of Epothilone B Employing Alkylation of an Alkyne for Assembly of Subunits" <i>Org. Lett.</i> , 1 (9):1431-1434, 1999.			
	Winkler, et al., "A Model for the Taxol (Paclitaxel) Epothilone Pharmacophore", <i>Bioorg., Med. Chem. Letter</i> , 6 : 2963-2966, 1996.			
	Winkler, et al., "Design and Synthesis of Constrained Epothilone Analogs: The Efficient Synthesis of Eleven-Membered Rings by Olefin Metathesis" <i>Tetrahedron</i> , 55 (27): 8199-8214, 1999.			
	Wittmann, et al., Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis, <i>Cancer Research</i> , 63 : 93-99, 2003.			
	Wolff, A., "Epothilone A Induces Apoptosis in Neuroblastoma Cells with Multiple Mechanisms of Drug Resistance", <i>Int. J. Oncol.</i> , 11 (1):123-126, 1997.			
	Woltering, et al., Development of a Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs, <i>Annals of Surgery</i> , 237 : 790-800, 2003.			
	Wu et al. "Subtle Variations in the Long-Range Transmission of Stereochemical Information: Matched and Mismatched Aldol Reactions" <i>Angew. Chem. Int. Ed.</i> 39 (24):4505-4508 (2000).			

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2003080-0071 (SK-744-CON4)	IN RE APPLICATION NO.:10/004,571
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT: Danishefsky <i>et al.</i>		
		FILING DATE: December 4, 2001	GROUP: 1626	
	Yang, et al., "Total Synthesis of Epothilone A: The Olefin Metathesis Approach: <i>Angew. Chem. Int. Ed.</i> , 36 : 166-168, 1997.			
	Yoshimura <i>et al.</i> , "Synthesis ad Conformational Analysis of (E)-9, 10-Dehydroepothilone B: A Suggestive Link between the Chemistry and Biology of Epothilones", <i>Angew. Chem. Int. Ed.</i> 42 :2518-2521, 2003.			
	Zhou, et al., Brominated Derivatives of Noscapine Are Potent Microtubule-Interfering Agents That Perturb Mitosis and Inhibit Cell Proliferation, <i>Molecular Pharmacology</i> , 63 :799-807, 2003.			
	Zhu, et al., "Methodology Based on Chiral Silanes in the Synthesis of Polypropionate-Derived Natural Products-Total Synthesis of Epothilone A" <i>Eur. J. Org. Chem.</i> , 9 : 1701-1714, 2001.			
	Zhu, et al., "Studies Toward the Total Synthesis of Epothilone A" <i>Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27, ORGN-660</i>			
	Zhu, et al.. "Enzymatic Resolution of Thiazole-Containing Vinyl Carbinols. Synthesis of the C12-C21 Fragment of the Epothilones" <i>Tetrahedron Lett.</i> , 41 (12):1863-1866, 2000.			
EXAMINER		DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

3805070

3753568v1